Skip to main content

Advertisement

Table 1 Characteristics of included studies

From: Combining scores from different patient reported outcome measures in meta-analyses: when is it justified?

Study groups Number of patients Intervention Wks of follow-up Study design Mean baseline scores (SD) Mean change scores (SD) Order of questionnaires randomized Use of validated questionnaires
      CRQ SGRQ CRQ SGRQ   
Barr [18] 102 Respiratory rehabilitation (RP) 4 Prospective follow-up study 3.89 (0.89) 55.8 (17.9) 0.71 (0.75) -3.00 (12.20) No Yes
Bestall [14] 23 RP 52 RCT 4.00 (0.90) 51.0 (13.7) 0.35 (0.85) -3.00 (12.20) No Yes
Bestall [14] 21 Patient education 52 RCT 4.28 (0.98) 51.9 (13.9) -0.05 (0.58) -1.00 (9.35) No Yes
Bourbeau [22] 65 RP 2 Prospective follow-up study n.a. n.a. 0.74 (0.74) -7.20 (12.30) Yes Yes
Bourbeau [22] 27 Usual care 2 Prospective follow-up study n.a. n.a. 0.35 (0.31) -2.40 (5.57) Yes Yes
Connor [16] 170 RP 52 Prospective follow-up study n.a. 51.6 (15.8) n.a. n.a. No Yes
Desikan [23] 40 Usual care 12 Prospective follow-up study 3.75 (0.95) 50.2 (18.5) 0.33 (0.86) -2.51 (9.71) Yes Yes
de Torres [19] 37 RP 8 Prospective follow-up study 4.13 (0.95) 52.0 (13.0) 0.56 (1.20) -4.00 (13.40) No Yes
Griffiths [20] 37 RP 52 RCT 3.59 (0.95) 64.9 (12.7) 0.25 (0.80) -3.40 10.86) No Yes
Griffiths [20] 33 Usual care 52 RCT 3.53 (0.95) 68.3 (13.3) -0.08 (0.80) 0.70 (10.86) No Yes
Hajiro [24] 165 Usual care 12 Prospective follow-up study 5.31 (0.97) 40.3 (20.1) 0.65 (0.83) -6.00 (18.50) No Yes
Harper [25] 156 Usual care 26 Prospective follow-up study 3.69 (0.95) 65.4 (15.9) 0.07 (1.00) 0.81 (9.95) No Yes
Man [17] 21 RP 18 RCT 2.64 (0.95) 65.4 (13.5) 1.87 (0.53) -16.10 (5.95) No Yes
Man [17] 21 Usual care 16 RCT 3.11 (0.95) 69.6 (13.6) 0.49 (0.26) -3.40 (8.50) No Yes
Rutten [9] 47 Salmeterol + Ipratropium 12 RCT 4.44 (0.81) 48.3 (13.9) 0.20 (0.60) -2.40 (11.00) No Yes
Rutten [9] 47 Salmeterol + Placebo 12 RCT 4.58 (1.03) 50.5 (16.6) -0.19 (0.80) -0.01 (7.10) No Yes
Rutten [9] 50 Placebo 12 RCT 4.22 (1.05) 50.2 (15.8) 0.03 (0.70) 0.50 (9.20) No Yes
Singh [12] 97 RP 7 Prospective follow-up study 3.66 (0.92) 58.8 (15.2) 0.72 (1.00) -4.02 (12.98) No Yes
Schunemann [8] 84 RP 12 Prospective follow-up study 4.01 (0.95) 52.8 (13.9) 1.14 (0.90) -8.10 (20.40) Yes Yes
Schunemann [10] 183 RP 12 Prospective follow-up study 4.57 (0.95) 50.6 (13.9) 0.55 (0.89) -5.43 (11.18) Yes Yes
Wedzicha [15] 26 RP on 8 RCT 3.76 (0.90) 56.7 (14.0) 0.20 (0.39) 3.00 (10.40) No Yes
Wedzicha [15] 28 Patient education 8 RCT 3.82 (1.20) 59.1 (13.0) 0.20 (0.32) 2.00 (8.10) No Yes
  1. RCT: Randomized controlled trial; n.a.: not available